EMA Broadens Valsartan Contamination Investigation

International Pharmaceutical Regulatory Monitor
A A
The EMA expanded its investigation of valsartan impurities after a new contaminant was discovered in an Indian manufacturer’s active substance, losartan.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $157.00